3/9/2010 · OBJECTIVE. In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide QW; 2 mg) was compared with exenatide BID in 295 patients with type 2 diabetes.
Both once daily liraglutide and once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with liraglutide. These findings, plus differences in injection frequency and tolerability, could inform therapeutic decisions for treatment of patients with type 2 diabetes.
9/16/2016 · To the best of our knowledge, DURATION-8 is the first prospective study to investigate the simultaneous addition of a GLP-1 receptor agonist (exenatide) and an SGLT2 inhibitor (dapagliflozin) for treatment of type 2 diabetes in patients with poor glycaemic control despite use of metformin.
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Buse JB(1), Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE; DURATION-1 Study Group.
Exenatide, sold under the brand name Byetta and Bydureon among others, is a medication used to treat diabetes mellitus type 2. It is used together with diet, exercise, and potentially other antidiabetic medication. It is a less preferred treatment option after metformin and sulfonylureas.
3/4/2010 · Objective: In the DURATION-1 study, the safety and efficacy of 30 weeks of treatment with the GLP-1 receptor agonist exenatide once weekly (exenatide QW; 2mg) was compared to exenatide BID in 295 patients with type 2 diabetes. We now report the safety and efficacy of exenatide QW in a) patients who continued treatment for an additional 22 weeks (52 weeks total), and b) patients who switched ...
6/1/2010 · OBJECTIVE In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide QW; 2 mg) was compared with exenatide BID in 295 patients with type 2 diabetes.
6/15/2010 · Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
5/1/2011 · The results of this study reinforce the results of a 30-wk, randomized, open-label study (DURATION-1), in which the continuous GLP-1 receptor agonism achieved with ExQW therapy demonstrated superiority to ExBID in reducing HbA1c in patients with type 2 diabetes .
6/25/2010 · Amylin Pharmaceuticals, Inc., Eli Lilly and Company, and Alkermes, Inc., announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON™ (exenatide extended-release for injectable suspension), an investigational Type 2 diabetes therapy, as compared to other Type 2 diabetes medications….
3/29/2006 · Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Although results across studies are not directly comparable, HbA1c reduction in the DURATION‐7 study was similar to that in a separate study evaluating exenatide BID added to titrated IG, 6 whereas, in the DURATION‐5 study, HbA1c reduction was significantly greater with exenatide QW vs exenatide BID. 33 This seemingly inconsistent finding ...
The median duration of exposure to the trial regimen was 2.4 years (interquartile range, 1.4 to 3.8) in the exenatide group and 2.3 years (interquartile range, 1.2 to 3.6) in the placebo group.
Aims. To investigate the glycemic efficacy, effects on cardiovascular risk factors, and safety of exenatide once weekly (QW) in patients with type 2 diabetes over 7 years in the DURATION-1 study.
Exenatide LAR, subsequently designated Exenatide once weekly Ex(OW), has been studied in a head to head comparison (DURATION-1) against twice daily exenatide, in a non-inferiority open label study over 30-wks, in 295 patients with type 2 diabetes (A1C 8.3±1.0%, FPG 168±42 mg/dL, weight 103±20 kg, BMI 35±5.0 kg/m2, diabetes duration 6.7±5.0 years; mean±SD).
6/8/2017 · Exenatide Once Weekly (QW) Plus dapagliflozin, exenatide QW, or dapagliflozin Added to metformin Monotherapy in Subgroups of Patients with type-2 Diabetes in the DURATION-8 Study (Poster 1115-P, Sunday June 11, 12:00 p.m. PDT)  The full list of AstraZeneca scientific presentations can be accessed on the ADA website here. NOTES TO EDITORS
Compared to Oral Antihyperglycemics. DURATION-2 was a 26-week randomized, double-blind, double-dummy study that compared the safety, efficacy, and tolerability of exenatide once weekly ...
The companies conducted DURATION-5 to support regulatory submissions outside of the U.S. and provide additional controlled clinical data on the commercially manufactured product. DURATION is a series of clinical trials designed to test the superiority of exenatide once weekly as compared to currently available Type 2 diabetes medications.
In this study, the exenatide QWS-AI formulation was compared with a DPP-4i. Another study (DURATION-NEO-1) compared the efficacy and safety of exenatide QWS-AI with exenatide BID in patients with T2D who were inadequately controlled with diet and exercise alone or with glucose-lowering therapies. After 28 weeks, mean (standard error) reductions ...
This post hoc analysis of three DURATION studies examined pooled efficacy and adverse events with exenatide QW from the 2.5- to 3-year completer populations; insulin glargine (glargine) was a reference (DURATION-3). Patients randomized to exenatide QW during the controlled study periods continued controlled treatment (DURATION-3) or single-arm ...
4/29/2011 · The once-weekly (QW) formulation of the glucagon-like peptide-1 receptor agonist exenatide has been demonstrated to improve A1C, fasting plasma glucose (FPG), body weight, serum lipid profiles, and blood pressure in patients with type 2 diabetes through 52 weeks of treatment. In this report, we describe the 2-year results of the open-label, open-ended extension to the DURATION-1 trial of ...